31st week of 2012 patent applcation highlights part 36 |
Patent application number | Title | Published |
20120195832 | PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION - The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent. | 2012-08-02 |
20120195833 | Medical Contrast Agent Made of Microbubbles Containing Fluorescent Gold Nanoclusters - A medical contrast agent made of microbubbles containing Au nanoclusters is provided. The shell of the microbubbles contains fluorescent Au nanocluster-albumin complex, and the core contains air or fluorocarbons. The method for preparing the microbubbles is also disclosed. | 2012-08-02 |
20120195834 | METHOD OF TESTING A DRUG FOR ANTI-CANCER ACTIVITY - A method for separating tumor cells with lymphotropic metastatic potential from those without lymphotropic metastatic potential in a human carcinoma. Cells of the carcinoma are transplanted in each of a plurality of fresh athymic mice. At least one of the athymic mice which does not develop a palpable tumor at the transplant site is treated to suppress the T-cell independent innate anti-tumor activity of natural killer cells therein. Tumor-forming cells at the transplant site of the treated athymic animal are harvested to obtain a cell line of cells with lymphotropic metastatic potential, which is also tested for the expression of T-lymphocyte associated molecules. Such cells are intimately associated with low or diminished angiogenicity and immunogenicity. The traditional scientific criteria for human cancer cells is re-defined, and therapeutic targets for human cancer cells is re-focused. | 2012-08-02 |
20120195835 | TUMOR TISSUE-SELECTIVE BIO-IMAGING NANOPARTICLES - A bio-imaging nanoparticle is composed of a core nanoparticle, a bonding layer having organic ligands, surfactants and polyoxyalkylene derivatives of fatty acid ester, and veiling the core nanoparticle, and functional molecules, wherein the organic ligands are bound to a surface of the core nanoparticle, the surfactants are bound to a portion of the surface of the core nanoparticle to which the organic ligands are not bound, the polyoxyalkylene derivatives of the fatty acid ester are introduced in an empty space between the organic ligands and the surfactants of the bonding layer, and the functional molecule is bound to a second terminal end opposite to a first terminal end of both terminal ends of the organic ligand, the first terminal end of the organic ligand being bound to a shell of the core nanoparticle. | 2012-08-02 |
20120195836 | Foamable Iodine Compositions - The present invention is related to a foamable composition of matter comprising iodine, water, a foam adjuvant, a surface-active agent and a gelling agent. This foamable composition, which may be provided in a propellant free foaming device, or alternatively may further comprise a propellant, evolves into foam, which is effective in the topical treatment and prevention of various skin disorders. | 2012-08-02 |
20120195837 | TIN(II)-2-HYDROXYCARBOXYLATES - The invention is drawn to a composition comprising a tin(II) 2-hydroxycarboxylate, where the 2-hydroxycarboxylate is preferably selected from the group consisting of glycolate, lactate, mandelate and 2-hydroxybutyrate. The tin(II) 2-hydroxycarboxylates may be prepared by a method comprising the steps of (a) providing an aqueous solution of a tin(II) salt, (b) adding a 2-hydroxycarboxylic acid, or a salt of a 2-hydroxycarboxylic acid, (c) further adding a base, wherein the tin(II) 2-hydroxycarboxylate precipitates, (d) optionally, isolating the tin(II) 2-hydroxycarboxylate, and (e) optionally, drying. The tin(II) 2-hydroxycarboxylates and compositions containing them are useful in oral care applications, and as catalysts for chemical condensation reactions and/or the production of polymers. | 2012-08-02 |
20120195838 | ORAL COMPOSITION FOR DENTURE WEARERS - Provided is an oral composition for denture wearers, which includes an antimicrobial substance of biological origin, is biocompatible, and has an antimicrobial activity. Specifically, provided is an antimicrobial oral composition for denture wearers including a component of common rush origin. The oral composition for denture wearers is placed in the mouth, and hence the oral composition for denture wearers including a component of common rush origin, which may also be used as a food additive, is safe for a living body and useful. | 2012-08-02 |
20120195839 | Film forming polymer compositions for boosting spf in sunscreens - Film-forming compositions comprising a film forming polymer containing acid groups and a neutralizing agent; compositions and methods for increasing the SPF of a composition by neutralizing at least a portion of the acid groups of the film forming agent with the neutralizing agent. | 2012-08-02 |
20120195840 | PERSONAL CARE COMPOSITION - The present invention relates to a personal care composition for topical application comprising selective fractions of natural materials having photoprotective and skin lightening applications. The inventors found that certain fractions of natural materials which are rich in anthroquinones or naphthaquinones e.g. those from the Rubiaceae family provide for enhanced broad spectrum photoprotection especially in the visible range while also exhibiting enhanced activity in a biochemical pathway viz. ty-rosinase inhibition which is indicative of improved skin lightening. | 2012-08-02 |
20120195841 | Sunscreen Cosmetic - The present invention provides a sunscreen cosmetic comprising, relative to the total amount of the sunscreen cosmetic, 10-90 wt % of agar microgel (wherein the agar content in the agar microgel is 0.4-1 wt %) and 0.1-5 wt % of a water soluble ultraviolet absorbent. | 2012-08-02 |
20120195842 | ENHANCED PHOTOSTABILITY OF SUNCARE COMPOSITIONS CONTAINING AVOBENZONE - The invention provides compositions and methods for enhancing the photostability of avobenzone in compositions for topical administration, including, e.g., sunscreen compositions, by addition of methyl anthranilate in an amount effective to stabilize avobenzone against photodegradation particularly where the composition is substantially free of other non-sunscreen agents that photostabilize avobenzone. | 2012-08-02 |
20120195843 | Emulsified Antiperspirant Composition And Method For Making Same - Antiperspirant compositions that include a continuous phase employing a water-immiscible liquid and a structurant, and a disperse phase employing a solution of antiperspirant active in water. | 2012-08-02 |
20120195844 | ESTERS AS PERFUMING INGREDIENTS - The present invention relates to some perfuming ingredients which are esters of formula (I) wherein R | 2012-08-02 |
20120195845 | DEODORANT AND DEODORIZING PRODUCT - An aldehyde gas deodorant dispersion composed of a mixture of an aminoguanidine salt that has a pH of 1 to 7 when dissolved in purified water and an acidic silica sol, the dispersion having a pH of 1 to 7, wherein a content of the aminoguannidine salt is 0.01 to 100 parts by weight relative to 100 parts by weight of a silica (SiO | 2012-08-02 |
20120195846 | DEGRADABLE HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) ACRYLATES AND GELS AND CONJUGATES DERIVED THEREFROM - A heterobifunctional poly(ethylene glycol) is provided having a hydrolytically degradable linkage, a first terminus comprising an acrylate group, and a second terminus comprising a target such as a protein or pharmaceutical agent or a reactive moiety capable of coupling to a target. Hydrogels can be prepared. The hydrogels can be used as a carrier for a protein or a pharmaceutical agent that can be readily released in a controlled fashion. | 2012-08-02 |
20120195847 | POLYMER CONJUGATES OF BIPHALIN PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer. | 2012-08-02 |
20120195848 | STRONTIUM-CONTAINING BIOACTIVE BONE CEMENT - The present invention provides bioactive bone cements that not only have sufficient radiopacity, low physiological toxicity, and requisite mechanism strength, but also promote local bone in-growth. The bone cement utilizes strontium salts as radiopacifiers, and comprises a powder component and a liquid component. In an embodiment, the powder component comprises a strontium salt, poly(methyl methacrylate) (PMMA), and a polymerization initiator; and the liquid component comprises methyl methacrylate (MMA) as reactive monomers and a polymerization accelerator. | 2012-08-02 |
20120195849 | ANTIMICROBIAL POLYMERS - The invention generally relates to novel polymers (SMAMPs) and their syntheses and use. The polymers exhibit promising properties of AMPs. In particularly, for example, a ring-opening metathesis polymerization (ROMP) platform was developed that allows syntheses of SMAMPs that employ a minimum number of norbornene-based building blocks and/or enable easy and independent variation of hydrophobic and hydrophilic groups in the monomer units and/or along the polymeric backbone to finetune and select desirable properties of the polymers. | 2012-08-02 |
20120195850 | USE OF POLYMER D-LACTIC ACID (PDLA) OR EQUIVALENTS THEREOF TO INHIBIT GROWTH OF CANCER CELLS AND DIAGNOSE CANCERS - The invention provides method for sequestering or trapping L-lactate in or near a tumor cell comprising contacting an isolated polymer of D-lactic acid (PDLA) or an equivalent, derivative or analog thereof with the tumor cell so that the PDLA binds L-lactate in or near the cell and thereby sequestering or trapping L-lactate in or near the tumor cells. | 2012-08-02 |
20120195851 | MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WITH IMPROVED BIOLOGICAL ACTIVITY - The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules. | 2012-08-02 |
20120195852 | VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME - Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed. | 2012-08-02 |
20120195853 | COSMETIC METHOD FOR TREATMENT OF SKIN AND HAIR WITH COSMETIC COMPOSITIONS CONTAINING INTERLEUKIN-1 - Cosmetic methods for treating skin and/or hair, including steps of (a) applying to skin and/or hair a cosmetic composition comprising interleukin-1 for 3 to 70 days, followed by (b) withdrawing application of the composition for 14 to 70 days, and (c) repeating steps (a)-(b) at least once. | 2012-08-02 |
20120195854 | GRANULYSIN IN IMMUNOTHERAPY - Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors. | 2012-08-02 |
20120195855 | METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS - The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against a tumor cell. Methods include administering to a subject with a tumor an amount of IFN-β receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell. | 2012-08-02 |
20120195856 | Method of treating patients with cardiovascular illness - This invention may be used in human and veterinary medicine in combination with traditional methods of treatment of cardiovascular illnesses for the purpose of increasing their effectiveness. | 2012-08-02 |
20120195857 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2012-08-02 |
20120195858 | RESPONSIVENESS TO ANGIOGENESIS INHIBITORS - The present invention relates to methods for improving the overall survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the vascular endothelial growth factor receptor 1 (VEGFR-1) gene. The present invention further provides methods for improving the progression-free survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the VEGFR-1 gene. The present invention also provides for methods for assessing the responsiveness of a patient to an angiogenesis inhibitor by determining the presence of one or more variant alleles of the VEGFR-1 gene. | 2012-08-02 |
20120195859 | RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS) - The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof. | 2012-08-02 |
20120195860 | LATENT NEURAL STEM CELL POPULATION - The present invention relates to a latent neural stem cell population which is capable of activation by membrane depolarization of a neural cell population, isolation and culture of same, and uses thereof. | 2012-08-02 |
20120195861 | METHODS AND COMPOSITIONS FOR PRODUCING GERM CELLS FROM PERIPHERAL BLOOD DERIVED GERMLINE STEM CELLS - Described herein are the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof. | 2012-08-02 |
20120195862 | BIOMECHANICAL INDUCTION OF HEMATOPOIESIS - The present invention provides methods and compositions for increasing the hematopoietic potential of a population of hematopoietic progenitor cells, vascular cells, and or hemogenic endothelium, by exposing the cells to at least one external biomechanical stimulus. More specifically, the application of shear stress to hematopoietic progenitor cells or endothelial cells stimulates hematopoiesis, with or without concurrent application of other extrinsic modulators of hematopoiesis. | 2012-08-02 |
20120195863 | METHODS AND APPARATUS FOR ENHANCED RECOVERY OF CELLS AND OF CELL-ENRICHED MATRIX FROM TISSUE SAMPLES - This document describes methods and an apparatus for recovery of a cell-enriched matrix and cells (e.g., regenerative cells) from a tissue sample. In some embodiments, at least two rounds of acceleration and deceleration are performed. | 2012-08-02 |
20120195864 | CELLS GENETICALLY MODIFIED TO COMPRISE PANCREATIC ISLET GLUCOKINASE AND USES THEREOF - The present invention relates generally to a population of cells genetically modified to comprise pancreatic islet glucokinase and capable of producing insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells so genetically modified capable of producing insulin in response to physiologically relevant levels of glucose and uses thereof. The cells of the present invention are useful in a wide variety of applications, in particular in the context of therapeutic and prophylactic regimes directed to the treatment of diabetes and/or the amelioration of symptoms associated with diabetes, based on the transplantation of the cells of the present invention into mammals requiring treatment. Also facilitated is the design of in vitro based screening systems for testing the therapeutic effectiveness and/or toxicity of potential adjunctive treatment regimes. | 2012-08-02 |
20120195865 | TRANSPLANTATION OF BONE MARROW STROMAL CELLS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS). | 2012-08-02 |
20120195866 | PKD Ligands and Polynucleotides Encoding PKD Ligands - The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate protein kinase D (PKD) activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to cellular localization signals, epitope tags and/or reporters. The invention also includes polynucleotides encoding the ligands and polyligands. | 2012-08-02 |
20120195867 | PROBIOTIC CONTAINING MODULES FOR TUBE FEEDING - The present invention relates to the field of enteral nutrition to be administered via tube feeding. In particular, the present invention provides tube feeding modules comprising probiotic micro-organisms. Such probiotic micro-organisms may be non-replicating micro-organisms, such as bioactive heat-treated probiotic micro-organisms, for example. | 2012-08-02 |
20120195868 | NUTRITIONAL COMPOSITIONS COMPRISING FIBER AND PROBIOTICS - Nutritional compositions including fiber blends having a stable amount of probiotics and methods of making the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including a fiber blend having agglomerated fiber particulates and a probiotic. The fiber blend can have a water activity of less than about 0.15. The nutritional composition can be in an administerable form such as pharmaceutical formulations, nutritional formulations, dietary supplements, functional foods and beverage products. | 2012-08-02 |
20120195869 | Sickled Erythrocytes with Anti-tumor Agents Induce Tumor Vaso-occlusion and Tumoricidal Effects - The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with at least one S hemoglobin allele which are capable of selectively localizing in tumor vasculature resulting in vaso-occlusion, hemolysis and heme release. A tumoricidal effect is achieved when these cells are administered in before during or after administration of (i) an agent(s) that interferes with degradation of reactive oxygen species, (ii) impairs glucose uptake and/or (iii) chemotherapy. These cells also carry oncolytic viruses, antitumor proteins, multidrug resistant proteins, chemotherapy, monoclonal antibodies, superantigens, superantigen conjugates and fusion proteins, siRNAs, plasmids and non-protein toxins and attenuated tumoricidal bacterial cells specifically into the tumors and induce a tumoricidal effect. | 2012-08-02 |
20120195870 | PREPARATIONS WITH WOOD EXTRACTS OF LOCUST TREES - The present invention relates primarily to the use of locust tree ( | 2012-08-02 |
20120195871 | STABLE AQUEOUS SUSPENSION - An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension. | 2012-08-02 |
20120195872 | ANTIMICROBIAL AGENTS - The present invention relates to antimicrobial agents against Gram-positive bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-positive bacteria and an additional peptide stretch fused to the enzyme at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-positive bacterial infections, as diagnostic means or as cosmetic substance. The present invention also relates to the treatment or prevention of Gram-positive bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Further, the present invention relates to a pharmaceutical composition comprising said fusion protein. | 2012-08-02 |
20120195873 | METHODS OF ATTENUATING THE LOSS OF FUNCTIONAL STATUS - Nutritional compositions and methods of using the nutritional compositions with exercise to attenuate the loss of functional status are provided. In a general embodiment, the present disclosure provides a nutritional composition including whey protein, and Vitamin D. The nutritional composition and exercise can be specifically used to attenuate the loss of functional status, especially in the elderly. | 2012-08-02 |
20120195874 | DFPASE ENZYMES FROM APLYSIA CALIFORNICA - The present invention relates to isolated polypeptides having organophosphorous hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. | 2012-08-02 |
20120195875 | DETECTION OF IMMUNE MODULATION RESULTING FROM REDUCED PROTEIN PHOSPHATASE 2A ACTIVITY - The inventors demonstrate herein that measuring the level of protein phosphatase 2A activity (PP2A) is useful for assessing immune modulation and susceptibility to infection in an individual. This invention is especially useful when applied to septic individuals, and individuals with chronic infections. The invention also teaches a method of prevention and treatment of secondary infections, as well as prevention and treatment of cancerous conditions. | 2012-08-02 |
20120195876 | NOVEL ROLE OF ALPHA-GALACTOSIDASE ACTIVITY AS A BIOMARKER IN KIDNEY DISEASE - Biomarkers for diagnosis and differentiation between stages of kidney diseases. Methods of treatments and identification of novel therapies are provided. | 2012-08-02 |
20120195877 | DEGRADABLE COMPOSITE MATERIAL CONTAINING CHITIN OR CHITOSAN - The object of the present invention is to provide a degradable composite material that contains at least one type of polysaccharide selected from chitin and chitosan, and has self-degrading capability. By supporting an enzyme capable of hydrolyzing chitin and chitosan on a molded article containing at least one type of polysaccharide selected therefrom, the polysaccharide can be slowly degraded in an environment where moisture is present such as a living body. | 2012-08-02 |
20120195878 | PROTOCOL FOR THE ADMINISTRATION OF BOTULINUM TOXINS - Embodiments of the invention provide treatment methods utilizing | 2012-08-02 |
20120195879 | CARRIER IMMUNOGLOBULINS AND USES THEREOF - Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide. | 2012-08-02 |
20120195880 | Modulation of Synaptic Maintenance - C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease. | 2012-08-02 |
20120195881 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE - In its many embodiments, the present invention provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (a) and pharmaceutically acceptable salts thereof. Compounds of Formula (a) have the general structure: (a) wherein each variable is selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers Disease, are also disclosed. | 2012-08-02 |
20120195882 | LIPOPARTICLE COMPRISING A PROTEIN AND METHODS OF MAKING AND USING THE SAME - Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a plurality of cellular virus receptor proteins are also described. Methods for making the enveloped virus vectors are described, as are methods of using the enveloped virus vectors. The invention further relates to a lipoparticle comprising a membrane spanning protein, and the lipoparticle can be attached to a sensor surface. The invention relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions. | 2012-08-02 |
20120195883 | MONOCOT SEED PRODUCT COMPRISING A HUMAN BLOOD PROTEIN - The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them. | 2012-08-02 |
20120195884 | METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre. | 2012-08-02 |
20120195885 | COMPOSITIONS CONTAINING GLYCOSYLATED ANTIBODIES AND USES THEREOF - The present invention provides compositions of antibodies, e.g., human antibodies, of varying glycosylation structures that serve to achieve desired rates of serum clearance. The invention also provides methods for modulating the pharmacokinetics of antibodies, e.g., human antibodies, and therapeutic compositions containing such antibodies. These methods rely on varying the glycosylation structures of the antibodies, e.g., human antibodies, to achieve desired rates of serum clearance. | 2012-08-02 |
20120195886 | SODIUM PUMP ANTIBODY AGONISTS AND METHODS OF TREATING HEART DISEASE USING THE SAME - Antibodies that are agonists of sodium pump (Na | 2012-08-02 |
20120195887 | Inhibitor Compounds and Cancer Treatment Methods - A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2. | 2012-08-02 |
20120195888 | Humanized Antibodies Against Human Interferon-Alpha - The present invention provides humanized anti-human IFN-α monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof. | 2012-08-02 |
20120195889 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO EPIDERMAL GROWTH FACTOR RECEPTOR MODULATORS - EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer. | 2012-08-02 |
20120195890 | OLIGONUCLEOTIDES INHIBITING CELLULAR MIGRATION - Oligonucleotides inhibiting cellular migration, and the use of at least one inhibitor of protein expression, which inhibits the expression of TSP1 protein, or a protein, which controls the expression of TSP1 or mediates the activity of TSP1, or one inhibitor of protein activity, this inhibitor inhibiting the activity of the TSP1 protein, in particular the activity responsible for the stimulation of cell migration, or one protein which controls the expression or mediates the activity of TSP1 for the manufacture of a drug for the prevention or the treatment of primary tumors or invasive or metastatic tumors. | 2012-08-02 |
20120195891 | METHODS, COMPOSITIONS, AND KITS FOR TREATING SHIGA TOXIN ASSOCIATED CONDITIONS - The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies. | 2012-08-02 |
20120195892 | IMMUNOGLOBULIN MOLECULES WITH IMPROVED CHARACTERISTICS - The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding. | 2012-08-02 |
20120195893 | TH1/TH2 polarizing vaccines - The present invention relates to recombinant chimeric molecules that are capable of providing T cell receptor (TCR) interaction and costimulation for activation and differentiation of pathogen-specific T cells toward effector T helper 1 (Th1) or T helper 2 (Th2) cells. The chimera may capable of elicit antibodies against pathogen-specific B cell epitope(s). The present invention also relates method of using these chimeric molecules in whole or as a component of a vaccine. | 2012-08-02 |
20120195894 | REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF - The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T | 2012-08-02 |
20120195895 | Fusion Protein of an Anti-CD20 Antibody Fab Fragment and Lidamycin, a Method for Preparing the Same, and the Use Thereof - The present invention relates to an anticancer drug, an energized fusion protein Anti-CD20(Fab)-LDM of lidamycin, a gene encoding the same; and further relates to a method for construction of the energized fusion protein in a genetic engineering manner and the use of the energized fusion protein. The applicant provides an anti-tumor drug with a good targeting ability by providing the energized fusion protein. | 2012-08-02 |
20120195896 | IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF - A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia. | 2012-08-02 |
20120195897 | HUMAN DOMAIN ANTIBODIES AGAINST COMPONENTS OF THE HUMAN INSULIN-LIKE GROWTH FACTOR (IGF) SYSTEM - The invention provides antibodies or antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as method of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer. The invention also provides a method of detecting the presence of IGF-1R or IGF-2 in a sample using the inventive antibodies and antibody fragments. | 2012-08-02 |
20120195898 | Immunizing Compositions and Methods of Use - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. | 2012-08-02 |
20120195899 | Immunizing Compositions and Methods of Use - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. | 2012-08-02 |
20120195900 | TRI-VARIABLE DOMAIN BINDING PROTEINS AND USES THEREOF - The present invention provides engineered multivalent and multispecific binding proteins, as well as methods of making them. Methods for using the multivalent and multispecific binding proteins of the invention in the prevention, diagnosis, and/or treatment of disease are also provided. | 2012-08-02 |
20120195901 | Compositions and Methods for Binding Lysophosphatidic Acid - Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. | 2012-08-02 |
20120195902 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASE - Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease (ESKD), and HIV-associated nephropathy (a distinct form of FSGS, also termed collapsing glomerulopathy). The compositions include the common variant of APOL1 and fragments thereof, as well as antibodies and fragments thereof that bind and neutralize pathogenic APOL1, nucleic acid molecules that encode the common variant of APOL1 and fragments thereof, and other compounds that bind and neutralize pathogenic APOL1. The methods of the invention include administering one or more of the compositions of the invention to a subject having or at risk of developing renal disease. | 2012-08-02 |
20120195903 | METHOD FOR THE PRODUCTION OF ANTIBODIES - The current invention is related to a method for the production of a human monoclonal antibody from a immundeficient non-human animal, said method comprising contacting a new borne immunodeficient non-human animal with a human fetal liver stem cell (FL cell) to generate an immune transplanted non-human animal (reconstituted animal), subsequently contacting said reconstituted animal with a antigen, collecting from said reconstituted animal a human cell producing human antibody against said antigen, and isolating said antibody from said antibody producing cell. | 2012-08-02 |
20120195904 | METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES - Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., K | 2012-08-02 |
20120195905 | TARGETED BINDING AGENTS DIRECTED TO DLL4 AND USES THEREOF 524 - The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL-4 and as diagnostics. | 2012-08-02 |
20120195906 | METHOD FOR DIAGNOSING AND TREATING EMPHYSEMA - The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3. | 2012-08-02 |
20120195907 | MONOCLONAL ANTIBODIES AGAINST THE PBP2-A PROTEIN AND HOMOLOGOUS SEQUENCES FOR THE TREATMENT OF INFECTIONS BY AND IMMUNODIAGNOSTICS OF BACTERIA OF THE FIRMICUTES PHYLUM - The present invention relates to monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant | 2012-08-02 |
20120195908 | COMBINATORIAL THERAPY - The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them. | 2012-08-02 |
20120195909 | ANTIBODIES AGAINST A PROLIFERATING INDUCING LIGAND (APRIL) - The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer. | 2012-08-02 |
20120195910 | ANTI-PCSK9 ANTIBODIES AND METHODS OF USE - The invention provides anti-PCSK9 antibodies and methods of using the same. | 2012-08-02 |
20120195911 | Method of treatment of cancer patients - This invention may be used in human and veterinary medicine in combination with traditional methods of treatment of oncological illnesses for the purpose of increasing their effectiveness. | 2012-08-02 |
20120195912 | Cripto Blocking Antibodies and Uses Thereof - The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications. | 2012-08-02 |
20120195913 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES - The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas. | 2012-08-02 |
20120195914 | ALDOSTERONE INDUCED ELASTIN PRODUCTION - Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein. | 2012-08-02 |
20120195915 | IAP BIR domain binding compounds - Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: | 2012-08-02 |
20120195916 | METHOD OF TREATING CANCER BY INHIBITING TRIM59 EXPRESSION OR ACTIVITY - A method of treating cancer in a mammal is provided comprising the step of inhibiting TRIM59 expression or activity in the mammal. TRIM59 expression may also be utilized in methods of diagnosing cancer in a mammal. | 2012-08-02 |
20120195917 | Vaccine Composition Comprising 5'-CAP Modified RNA - The present invention relates to modification of RNA with 5′-cap analogs in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA. | 2012-08-02 |
20120195918 | METHOD OF TREATING CANCER WITH AN HLA-A*3303-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and others. | 2012-08-02 |
20120195919 | HYBRID AND TANDEM EXPRESSION OF NEISSERIAL PROTEINS - Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH | 2012-08-02 |
20120195920 | STAPHYLOCOCCUS AUREUS DIV1B FOR USE AS VACCINE - The invention relates to an antigenic polypeptide referred to as DivlB and variants thereof, vaccines comprising said polypeptide and the use of the vaccine in protecting subjects from microbial infection. | 2012-08-02 |
20120195921 | RECOMBINANT T-CELL RECEPTOR LIGAND FOR THE TREATMENT OF COGNITIVE AND NEUROPSYCHIATRIC IMPAIRMENT INDUCED BY SUBSTANCE ADDICTION - Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system. | 2012-08-02 |
20120195922 | METHODS FOR PREPARING COMPLEX MULTIVALENT IMMUNOGENIC CONJUGATES - Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. | 2012-08-02 |
20120195923 | USE OF SKIN CARE COMPOSITIONS COMPRISING LAMINARIACEA EXTRACT FOR TREATMENT OF SKIN AGING SIGNS - This invention is directed to a skin care composition comprising a laminriacea (brown seaweed) extract and the use of said composition in the treatment of skin aging signs Specifically, it was discovered that a crude extract of the laminariacea | 2012-08-02 |
20120195924 | ADENOVIRAL VECTOR VACCINE - Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term. | 2012-08-02 |
20120195925 | Vaccines with increased immunogenicity and methods for obtaining them - Vaccines with increased immunogenicity, distinct in that in the capacity of a specific immunogenic component, whole vaccine antigens or vaccine antigens that have been cut into oligomer fragments are used; the mixture (assembly) of oligomer fragments or whole antigen obtained is modified by changing its molecular charge to the opposite. | 2012-08-02 |
20120195926 | METHODS OF IMPROVING VACCINE IMMUNOGENICITY - The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing anti-body response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine. | 2012-08-02 |
20120195927 | GM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS - The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements. | 2012-08-02 |
20120195928 | VACCINES AND METHODS FOR USING THE SAME - Compositions comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments thereof and/or an isolated nucleic acid molecule that encodes a protein selected from the group consisting of: CTACK, TECK, MEC and functional fragments thereof are disclosed. Methods of inducing an immune response, including methods of inducing mucosal immune responses, in an individual against an immunogen, using such compositions are disclosed. | 2012-08-02 |
20120195929 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME - The invention provides methods of preventing, treating or ameliorating autoimmune diseases such as diabetes by modulating the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same. | 2012-08-02 |
20120195930 | NOVEL PYRIDINE DERIVATIVES - The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents. | 2012-08-02 |
20120195931 | POLYCHLORINATED BIPHENYLS AND SQUALENE-CONTAINING ADJUVANTS - When using squalene in a vaccine adjuvant, there is a possibility of contamination with polychlorinated biphenyls (PCBs). Environmental exposure to PCBs may adversely affect children's immune responses to routine vaccinations. Thus the invention uses squalene with low or no PCB contamination, particularly when derived from shark liver. | 2012-08-02 |